Chronoscale Holdings Corp annual report, FY2024

Business Context and Reporting Period

Company: Ekso Bionics Holdings, Inc. (Ticker: EKSO)
Filing Type: Form 10-K (Annual Report)
Period Ended: December 31, 2024
Business Overview: Ekso Bionics designs, develops, and markets robotic exoskeletons for healthcare (rehabilitation and mobility) and industrial applications. The company operates as a single segment with two primary markets: Enterprise Health (clinical settings) and Personal Health (home/community use for individuals with spinal cord injuries). Key products include EksoNR, Ekso Indego Therapy, Ekso Indego Personal, and the industrial EVO exoskeleton.

Key Financial Metrics

Metric 2024 2023
Revenue $17.9 million $18.3 million
Gross Profit $9.5 million $9.1 million
Gross Margin 53% 50%
Net Loss $(11.3) million $(15.2) million
Operating Loss $(10.5) million $(15.1) million
Cash and Restricted Cash (End of Period) $6.5 million $8.6 million
Unrestricted Cash ~$4.5 million N/A
Working Capital $11.3 million $12.1 million
Accumulated Deficit $(250.5) million $(239.2) million

Debt Obligations: The company holds a secured term loan with Banc of California (due August 2026) and a subordinated promissory note to Parker Hannifin Corporation (maturing September 2027). Total contractual obligations for debt and leases exceed $6.6 million.

Material Changes vs. Prior Period

  • Revenue: Decreased 2% ($0.4 million) primarily due to lower average selling prices and reduced EksoNR subscription volumes, partially offset by increased service revenue.
  • Profitability: Gross margin improved to 53% from 50% driven by supply chain cost savings and reduced service costs. Net loss narrowed by 25% ($3.9 million) due to significant reductions in operating expenses.
  • Operating Expenses: Total operating expenses decreased 17% ($4.2 million). Sales and marketing, R&D, and G&A expenses all declined significantly due to lower headcount and discretionary spending.
  • Other Income/Expense: The company recorded a $0.5 million gain on the revaluation of warrant liabilities in 2024 compared to a loss in 2023. However, this was offset by a $1.0 million unrealized loss on foreign exchange.
  • Cash Flow: Net cash used in operating activities decreased to $9.8 million from $12.1 million. Financing activities provided $7.8 million in 2024, driven by equity offerings in January and September.

Guidance, Outlook, Risks, and Unusual Items

Outlook and Management Commentary

  • Medicare Reimbursement: In April 2024, CMS approved a payment level of approximately $91,000 for the Ekso Indego Personal device. The company is currently refining its reimbursement process with Durable Medical Equipment (DME) suppliers and has paused direct sales to DMEs for CMS reimbursement while resolving appeals on pending claims.
  • Going Concern: Management has raised substantial doubt about the company's ability to continue as a going concern for the next 12 months. Cash on hand is insufficient to fund operations without additional financing. The company is actively seeking capital through equity or debt offerings.
  • Manufacturing: The company plans to transfer partial production of Ekso Indego Personal and Therapy to a third-party contract manufacturer in the U.S. by Q1 2025 and consolidate final assembly in San Rafael by Q2 2025.

Risks and Contingencies

  • Nasdaq Listing Compliance: The company received notice from Nasdaq that its stock price has been below the $1.00 minimum bid price requirement for 31 consecutive days. It has until June 10, 2025, to regain compliance or face delisting.
  • Regulatory: The company is transitioning its European products to comply with the EU Medical Device Regulation (EU MDR). While Ekso Indego Therapy and Personal received CE certificates in February 2025, the EksoNR application is pending.
  • Intellectual Property: The company relies on licenses from UC Berkeley and Vanderbilt University. Failure to meet royalty obligations or diligence requirements could result in termination of these critical licenses.

Investor Verification Checklist

  • Liquidity Status: Verify the company's progress in securing additional financing to address the "substantial doubt" regarding its ability to continue as a going concern.
  • Stock Price Compliance: Monitor the stock price to determine if the company will meet the Nasdaq minimum bid price requirement by June 10, 2025, or if a reverse stock split is required.
  • Reimbursement Execution: Track the volume of successful CMS reimbursement claims for the Ekso Indego Personal device and the resolution of current appeals.
  • Debt Covenants: Confirm continued compliance with the Banc of California loan agreement, specifically the liquidity covenant requiring cash on hand to equal the outstanding principal balance.
  • EU MDR Status: Verify the timeline for receiving EU MDR certification for the EksoNR product to ensure continued sales in the European market.
Disclaimer:
This AI-generated summary by MetaQuotes is based on SEC filings and may contain errors. Verify important details against the original SEC filings.